Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Journal of Clinical Pharmacology|May 18, 2013
Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosusHerbert Struemper, Cecil Chen, Wendy Cai
Clinical Pharmacology in Drug Development|November 27, 2020
Pharmacokinetics of Belimumab in Children With Systemic Lupus ErythematosusRichard Dimelow, Beulah Ji, Herbert Struemper
Clinical Pharmacokinetics|September 10, 2017
Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus ErythematosusHerbert Struemper, Mita Thapar, David Roth
Modern Rheumatology|May 25, 2018
Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trialYoshiya Tanaka, Damon Bass, Myron Chu, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 2, 2021
Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myelomaChetan Rathi, Jon Collins, Herbert Struemper, et al.
Lupus Science & Medicine|February 8, 2022
Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLEHerbert Struemper, Milena Kurtinecz, Lisa Edwards, et al.
Clinical Therapeutics|August 3, 2020
Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose StudyBruce A Hug, Christopher J Matheny, Olivia Burns, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 19, 2023
Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myelomaJon Collins, Martijn van Noort, Chetan Rathi, et al.
Clinical Pharmacology and Therapeutics|September 1, 2021
Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple MyelomaGeraldine Ferron-Brady, Chetan Rathi, Jon Collins, et al.
International Journal of Clinical Pharmacology and Therapeutics|September 27, 2016
Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosusSaira Z Sheikh, Anne E Hammer, Norma Lynn Fox, et al.
Pageof 3